<aside> 💡

Kevo-Prophen is a clinically validated, plant-based topical cream designed for effective relief of musculoskeletal pain. Leveraging advanced aromatic and herbal science, Kevo-Prophen delivers targeted, non-opioid pain management with an 80–90% plant-based formula, reducing reliance on synthetic chemicals. Its efficacy is supported by patient outcomes, case studies, and clinical trial-based research, ensuring both safety and performance.

</aside>

<aside> 💡

Sun Butter: Plant-Based Innovation for Burn and Skin Recovery

Sun Butter was originally formulated following a surfing accident in Florida, where its effectiveness in soothing sunburn inspired further development. Recognizing its potential, the formula was refined in Faeve’s laboratory for commercial production, resulting in a best-selling product within our portfolio.

Initially adopted for sunburn relief, Sun Butter quickly gained traction among healthcare practitioners—particularly those treating patients with burns from breast cancer radiation and other topical skin conditions. Preliminary feedback also suggests efficacy in reducing hives, though additional research is underway to validate these findings.

Broker insights highlight Sun Butter’s broad market appeal, describing it as a multi-generational solution suitable for diverse age groups and skin concerns. The product is 100% plant-based and will be protected by a trademarked, proprietary blend, positioning SunG Butter as a differentiated leader in the natural skin recovery segment.

</aside>

<aside> 💡

Diabetic Product: Plant-Based Innovation for reduction in blood glucose and A1C

One year ago, we were approached by an industry contact with a challenge: could we develop a topical product to support individuals with diabetes? After six months of focused research and formulation, we successfully created a prototype and conducted preliminary testing with 20 participants, all of whom had either pre-diabetes or diabetes. In every case, participants experienced a reduction in blood sugar levels. Notably, one tester reported that our product worked better for him than metformin alone and requested additional supply.

While these early results are promising, advancing this product will require significant time and resources for full clinical validation. For this reason, it remains third on our development priority list.

</aside>